C-Path’s TRxA Announces its First Global Request for Proposals from Academic Investigators Working to Advance Drug Development Projects

Launched in 2022, the Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. TRxA is now accepting applications for its 2023 funding cycle.

As a nonprofit drug accelerator, TRxA provides the following for principal investigators who are selected to receive an award:

  • Resources and hands-on guidance, working closely with academic researchers to develop comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies to invest in clinical trials.
  • Tactical and strategic drug discovery and development leadership, including regulatory science considerations, bringing diverse expertise to pivotal early-stage academic study designs and implementation.
  • Engagement of contract research organizations (CRO) to perform critical discovery phase experiments (e.g., key toxicology and other specialized studies) and/or validate academic studies to develop the type of comprehensive data package pharmaceutical companies require when licensing drug products.

Learn more about TRxA


To learn more about this funding opportunity, click here for TRxA’s Guidance Document for Applicants. Also, be sure to register for the 2023 TRxA Funding Opportunities webinar at 10 AM ET, February 8. Content will include an overview of the types of projects TRxA funds, eligibility criteria for TRxA awards, and details about how to apply before the first submission deadline of April 17, 2023. The webinar will conclude with a live Q&A.

Posted in AZBio News.